Startups Funded in 2010

Money

18 major Ortho fundings = $240M

—————————————

Dec 2010

Bonovo (China) Hip, knee and instrument maker raises $16.5M in Series C round

Sep 2010

Ranier Technology (UK) secures $8M to commercialise its Cadisc-L spinal disc in Europe

Aug 2010

Bacterin Medical (Belgrade, MT) closes $9.2M in Private Placement. Bacterin is a developer of anti-infective coatings for medical applications and revolutionary bone graft material.

http://www.bacterin.com

——————————————————————–

July 2010

BioMimetic Theraeutics (Nashville, TN) raised $45M with a public offering of 5,000,000 shares of stock

http://www.biomimetics.com

DFine (San Jose, CA) VC round of $36.2M led by new investor Split Rock Partners. Funding was also contributed by new investor OrbiMed, and inside investors Prospect Venture Partners, Vanguard Ventures, BBT Fund/Apothecary Capital, Highland Capital Management and several private investors. DFine is a developer of minimally invasive solutions for treating vertebral pathologies.

http://www.dfineinc.com/

Del Palma Orthopedics (Comlumbia City, IN) raised $1.4M for it’s trigger finger procedure kit. Del Palma is housed in the OrthoVation Center incubator.

http://www.delpalmaortho.com/

Bio2Tech (Boston) $1.1M in Angel funding to develop new biomaterials, spinoff of Geo2 Technologies

http://www.bio2tech.com

——————————————————————–

June 2010

Baxano Inc (Moutain View, CA) $30M in Series C ed by new investor CMEA Capital, founded 2005, instrumentation to restore spine function and preserve healthy tissue

http://www.baxano.com

Anulex Technologies (Minnetonka, MN) completes $20M in Series E financing to expand commercialization and complete the follow-up phases for Xclose

http://www.anulex.com

——————————————————————–

Apr 2010

Articulinx (Cupertino, CA) raises $10M in Series B financing to further develop interpositional spacers for hand osteoarthritis. http://www.articulinx.com

——————————————————————–

Mar 2010

Anulex Technologies (Minnetonka, MN) raises $3.8M with 11 investors.  The most recent cash infusion brings Anulex’s total funding to around $52 million since 2003. The company closed its fourthround of funding in June, pulling in $10.2 million from a number of investors.Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners

Carticept Medical, Inc., (Alpharetta, GA) a developer of innovative products for the treatment of cartilage injuries and osteoarthritis.   New investor SonoSite, Inc. joined existing investors Domain Associates and New Enterprise Associates. The financing will provide funding for the expected commercial launch of the Company’s NavigatorTM Delivery System, an integrated, computer-controlled, fluid delivery system designed to automate the delivery of medication for the benefit of both the patient and physician, as well to complete patient enrollment in the clinical study of the Company’s CartivaTM Synthetic Cartilage Implant.

http://ow.ly/1kzXZ

——————————————————————–

Feb 2010

Intrinsic Therapeutics Inc (Woburn, MA) raised $18M out of a $20M offering, according to a regulatory filing with the federal SEC.  No new investors were listed on the filing. However, previous investors New Enterprise Associates and Spray Ventures were listed as board members, both firms have been with Intrinsic since their initial investment of $7.2M in 2001. Another VC firm, New Leaf Venture Partners (formerly Sprout Group), which invested in the company’s $25M round back in 2003 was also listed on the SEC form D. The company has a total of 11 investors overall.  Intrinic won the CE mark of approval for its Barricaid annular prosthesis in April, 2009. The device is a partial-disc prosthesis that enables surgeons to reconstruct the annulus (a fibrous ring around the edge of the intervertebral disc) during standard discectomies in patients with lumbar disc herniations and sciatica.

http://ow.ly/1c4OP

Intralink-Spine (ILS) awarded a $750,000 Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) for pre-clinical studies of its NEXT technology, develoing a tissue modifying reagent that can be injected into the intervertebral disc of the human spine to increase crosslinking in the native collagen matrix

http://www.intralink-spine.com

——————————————————————–

Jan 2010

OrthoAlign (Irving, CA) concluded its Series A financing round with a $5.2 million Series A2 tranche led by California Technology Ventures. Additional participants included Research Corporation Technologies and Okapi Venture Capital. ”This round of financing provides us with the capital to launch our first product, the KneeAlign system, in 2010, and to continue developing other products in our pipeline,” said CEO Pieter Wolters

http://orth-align.com

BioCeramic Therapeutics (UK) a development-stage provider of bioactive materials for orthopaedic and dental applications, closed a $1.9M Series B financing. Participants include Imperial Innovations, Longbow Capital Partners, Comvest and Esmee Fairbairn Foundation.

http://ow.ly/YO41

http://www.bioceramictherapeutics.com/

BioPoly LLC (Fort Wayne, IN) a Schwartz Biomedical subsidiary, has raised more than $2M in its first round of equity financing. This capital will be used to complete product development and initiate launch of its first orthopaedic products into the market.  http://ow.ly/WDbN

Salient Surgical Technologies (Portsmouth, NH) has raised $15 million in equity-based financing from a group of 10 unnamed investors.  Founded in 1999, it was formerly known as Tissuelink Medical, Salient makes devices that stop bleeding and seal wounds by allowing surgeons to apply focused radio-frequency energy and saline solution to collagen fibers in the body. Salient raised $17.9 million in Series F in Oct 2008 shortly after withdrawing plans for an $86 million initial public offering.

http://ow.ly/Us8J

MiMedx Group (Atlanta) raised $5M in Private Placement.  MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and is in the process of transitioning from a development-focused concern to an operating company focused on sales growth and profitability. The proceeds of the offering will be used to support the Company’s launch of its first product, the Paradis Vaso Shield.

February 22, 2012

  • Editor – Tiger Buford

  • Recruiting Partner

  • most popular this week

  • Monthly Articles

  • RSS Orthopedics This Week

  • RSS MedPageToday

  • Support OrthoStreams

  • Newsletter Signup